Walleye Capital’s BeOne Medicines Ltd ONC Stock Holding History

Walleye Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Sell	723 -20,328	-97%	-$5.99M	﹤0.01%	3487
2026 Q1	$6.25M	Buy	21,051 +18,109	+616%	+$5.86M	0.03%	659
2025 Q4	$894K	Buy	+2,942	New	+$963K	﹤0.01%	2531
2025 Q3	–	Sell	-36,645	Closed	-$8.87M	–	5267
2025 Q2	$8.87M	Sell	36,645 -36,102	-50%	-$8.85M	0.03%	566
2025 Q1	$19.8M	Buy	72,747 +68,248	+1,517%	+$16M	0.09%	209
2024 Q4	$831K	Sell	4,499 -22,222	-83%	-$4.54M	﹤0.01%	2550
2024 Q3	$6M	Buy	26,721 +11,624	+77%	+$2.09M	0.01%	1038
2024 Q2	$2.15M	Buy	15,097 +13,624	+925%	+$2.1M	﹤0.01%	2030
2024 Q1	$230K	Buy	+1,473	New	+$237K	﹤0.01%	3883
2023 Q4	–	Sell	-7,788	Closed	-$1.41M	–	5626
2023 Q3	$1.4M	Buy	+7,788	New	+$1.54M	﹤0.01%	1996

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital's ONC Position: Q2 2026 in Review

Walleye Capital reduced its BeOne Medicines Ltd (ONC) stake by 97% in Q2 2026, selling an estimated $5.99M and leaving 723 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Walleye Capital first reported a position in ONC in Q3 2023 and has held it in 10 quarters since. The position peaked at $19.8M in Q1 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Walleye Capital held 723 shares of BeOne Medicines Ltd worth $206K as of Q2 2026.
Walleye Capital sold 20,328 BeOne Medicines Ltd shares in Q2 2026, an estimated $5.99M.
BeOne Medicines Ltd made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3487 holding.
Walleye Capital first reported a position in BeOne Medicines Ltd in Q3 2023 and has held it in 10 quarters since.
Walleye Capital's BeOne Medicines Ltd position peaked at $19.8M in Q1 2025.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.